Mirikizumab

Mirikizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL23A, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Mirikizumab is a humanized IgG4 monoclonal antibody that targets p19 subunit of IL-23. Currently, mirikizumab is being developed for a variety of immune diseases, including psoriasis, UC, and Crohn's disease (CD). Among them, the treatment of moderate to severe plaque psoriasis is in phase III clinical trials.

Target	IL23A
Clonality	Monoclonal
Reactivity	Human
Expression	Recombinant
Tested Applications	ELISA, WB
Host	Human
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Isotype	IgG4 Kappa
Form	Liquid
Purity	> 95%
Purification	Purified from cell culture supernatants by Protein A/G chromatography.
Storage	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Buffer	0.01 M PBS. pH 7.4.
CAS Number	1884201-71-1
Concentration	Batch-dependent, typically between 0.5-2.0 mg/ml.
Availability	Shipped within 7-12 working days.
Note	This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use.

Research Articles on IL23A

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue